Search

Displaying results 9841 - 9850 of 10000 in total
  1. Drug

    Phosphorus P-32

    go.drugbank.com/drugs/DB14551
    Investigational

    Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular

  2. Drug

    Telisotuzumab adizutecan

    go.drugbank.com/drugs/DB21832
    Investigational

    Telisotuzumab Adizutecan is under investigation in clinical trial NCT06614192 (A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and

  3. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  4. Drug

    RO7284755

    go.drugbank.com/drugs/DB17527
    Investigational

    RO7284755 is under investigation in clinical trial NCT04303858 (A Study to Evaluate Safety and Anti-tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced And

  5. Drug

    SPL84-23-1

    go.drugbank.com/drugs/DB18575
    Experimental

    SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence

  6. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  7. Drug

    Ferrous succinate

    go.drugbank.com/drugs/DB14489
    ApprovedInvestigational

  8. Drug

    Ferrous ascorbate

    go.drugbank.com/drugs/DB14490
    ApprovedWithdrawn

  9. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.

  10. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]